Rosy Phase 1 results for ImmunoGen drug

Nov. 16, 2005 at 2:15 PM

CAMBRIDGE, Mass., Nov. 16 (UPI) -- ImmunoGen said Wednesday that its investigational drug dubbed huN901-DM1 shows promise in fighting solid tumors.

The compound appears to cause complete remission in patients with small-cell lung cancer or other CD56-expressing solid tumors, lasting at least 15 weeks, and disease stability lasting up to 18 weeks, the Cambridge, Mass.-based firm said in a statement.

ImmunoGen presented its Phase 1 clinical findings on the tumor-activated prodrug compound at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.

In the ongoing trial, the drug is being administered daily for three consecutive days in a 21-day cycle to patients with CD56-expressing solid tumors, ImmunoGen said.

New cohorts of patients receive progressively higher doses of huN901-DM1 until the maximum tolerated dose is established, the company said.

All study patients have relapsed or refractory small-cell lung cancer (SCLC) or other CD56-expressing solid tumors.

Related UPI Stories
Latest Headlines
Trending Stories
Females with childhood ADHD at double the risk for obesity
Medicaid-paid births up in Texas since defunding Planned Parenthood
New ethics standards for DNA replacement therapies
New screening method detects all cystic fibrosis mutations
Esophageal cooling device helps doctors control body temperature